Specific CD8+ T cell clones in ITP, Refining DLBCL prognosis with the “dark-zone signature”, and rethinking the regenerative role of HSCs in acute hematopoietic emergencies
Blood Podcast
00:00
The Role of Cell of Origin in the Treatment of Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma is an aggressive but curable disease. But for those who relapse or are refractory to frontline treatment, outcomes are poor. The majority of DL-BCL can be dichotomized into the German National Center B-Cell-Like Subgroup (GCB) GCB patients have a three-year rate of progression-free survival that's 15 to 25 percent higher than ABC DL-BCl.
Transcript
Play full episode
